Pfizer said to be adding $5B to AZ bid

Share this article:

Pfizer has sweetened the pot in its bid for AstraZeneca, Bloomberg reports. The new deal could reach $106 billion, according to a source the news service says is close to the matter.

An offer last week hovered in the $101-billion range, according to recent reports.

If the deal goes through, it would give Pfizer a lower tax rate and grant it access to a number of investigational cancer drugs.

Ian Read met with British lawmakers on April 29 to discuss the bid, according to another Bloomberg source, and the CEO “emphasized the American company's plans to carry out research, development and manufacturing in the UK, as well as the appeal of the British tax system.”

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.